课题基金 / 基金详情

ROLE OF PKC IN CELL TURNOVER IN THE MAMMARY GLAND

ROLE OF PKC IN CELL TURNOVER IN THE MAMMARY GLAND
PKC 在乳腺细胞更新中的作用
批准号:
7018039
负责人:
MARY ELAINE REYLAND
金额:
$16.05万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-07-01 至 2010-05-31

项目摘要

项目成果

MARY ELAINE REYLAND的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Mammary gland development and involution are complex processes which are regulated in part through dynamic changes in cell proliferation and apoptosis. In the mammary gland apoptosis contributes to ductal development and is essential for the clearance of mammary epithelial cells during post-lactational involution. Protein kinase Cdelta (PKCdelta) is a ubiquitously expressed isoform of the PKC family of serine/threonine kinases, and analysis of the mouse knock-out of PKCdelta suggests that this isoform regulates both cell proliferation and apoptosis. Our studies indicate that PKCdelta functions early in the apoptotic pathway and we have recently identified Signal Transducer and Activator of Transcription 1 (STAT1) as a downstream target of PKCdelta in apoptotic cells. PKCdelta is also essential for STAT3 activation in cells treated with cytokines and interferon. In the mammary gland, STATS is required for mammary gland development during pregnancy, while STATS orchestrates mammary gland involution. The central role PKCdelta plays in epithelial cell apoptosis, together with the link between PKC5 and STAT activation, suggests that PKCdelta may be critical for mammary gland homeostasis. In this proposal we will explore the role of PKCdelta in mammary gland development and involution using mice in which the PKCdelta gene has been disrupted (deltaKO mice) and primary mammary epithelial cells derived from wild type and deltaKO mice. In Aim 1 we will test the hypothesis that loss of PKCdelta in vivo result in suppression or delay of involution and may result in abnormal mammary gland development. We will determine if mammary gland development and/or involution are altered in PKCdelta knock-out (deltaKO) mice, if the mammary gland phenotype in the deltaKO mice is tissue autonomous, and if reconstitution of PKCdelta can reverse the phenotype. In Aim 2 we will explore the molecular mechanisms by which PKCdelta regulates mammary epithelial cell apoptosis, and we will test the hypothesis that PKCdelta is required for signal transduction downstream of prolactin and the IL6 family cytokines. We will explore PKCdelta activation in response to apoptotic stimuli relevant to involution and determine the functional domains of PKCdelta that are required for apoptosis in MECs. We will determine if MECs from deltaKO mice are resistant to apoptosis induced by these stimuli and explore the molecular mechanism which underlies this resistance. The proposed studies will enhance our understanding of the signal transduction pathways which regulate mammary gland development and involution.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Colorado HNC SPORE Developmental Research Program
  • 批准号:
    10477468
  • 项目类别:
  • 资助金额:
    $9.56万
  • 财政年份:
    2021
  • 负责人:
    MARY ELAINE REYLAND
  • 依托单位:
Colorado HNC SPORE Developmental Research Program
  • 批准号:
    10704605
  • 项目类别:
  • 资助金额:
    $9.56万
  • 财政年份:
    2021
  • 负责人:
    MARY ELAINE REYLAND
  • 依托单位:
Colorado HNC SPORE Developmental Research Program
  • 批准号:
    10268848
  • 项目类别:
  • 资助金额:
    $10.28万
  • 财政年份:
    2021
  • 负责人:
    MARY ELAINE REYLAND
  • 依托单位:
Cancer Research Experiences for Undergraduates (CREU)
  • 批准号:
    9792114
  • 项目类别:
  • 资助金额:
    $32.4万
  • 财政年份:
    2019
  • 负责人:
    MARY ELAINE REYLAND
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
  • 批准号:
    31970691
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    张胜萍
  • 依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
  • 批准号:
    31900527
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2019
  • 负责人:
    孙磊
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位: